Richard Letrero

3.3k total citations
12 papers, 1.3k citations indexed

About

Richard Letrero is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Richard Letrero has authored 12 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 2 papers in Organic Chemistry. Recurrent topics in Richard Letrero's work include Melanoma and MAPK Pathways (8 papers), Cutaneous Melanoma Detection and Management (5 papers) and Cancer Mechanisms and Therapy (2 papers). Richard Letrero is often cited by papers focused on Melanoma and MAPK Pathways (8 papers), Cutaneous Melanoma Detection and Management (5 papers) and Cancer Mechanisms and Therapy (2 papers). Richard Letrero collaborates with scholars based in United States, Australia and Netherlands. Richard Letrero's co-authors include Katherine L. Nathanson, Keith T. Flaherty, M. Celeste Simon, Brian Keith, Vijay R. Dondeti, W. Kimryn Rathmell, John D. Gordan, Priti Lal, Roger A. Greenberg and Meenhard Herlyn and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and Molecular and Cellular Biology.

In The Last Decade

Richard Letrero

12 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Letrero United States	10	976	417	366	297	257	12	1.3k
Kurt D’Andrea United States	14	452 0.5×	238 0.6×	235 0.6×	82 0.3×	185 0.7×	23	872
Bradley Wubbenhorst United States	14	449 0.5×	281 0.7×	311 0.8×	173 0.6×	124 0.5×	28	1.0k
Dineli Wickramasinghe United States	17	953 1.0×	359 0.9×	161 0.4×	312 1.1×	107 0.4×	24	1.6k
Gayatry Mohapatra United States	14	743 0.8×	517 1.2×	320 0.9×	486 1.6×	85 0.3×	26	1.4k
Felipe C. Geyer United Kingdom	20	600 0.6×	566 1.4×	688 1.9×	152 0.5×	168 0.7×	30	1.5k
Sanjay Koul United States	15	1.1k 1.1×	386 0.9×	246 0.7×	288 1.0×	236 0.9×	21	1.6k
François Ringeisen France	14	517 0.5×	373 0.9×	175 0.5×	305 1.0×	85 0.3×	33	899
Kim Wilber Switzerland	14	787 0.8×	627 1.5×	395 1.1×	224 0.8×	202 0.8×	16	1.5k
María Ángeles López‐García Spain	19	1.1k 1.1×	735 1.8×	946 2.6×	287 1.0×	85 0.3×	27	1.9k
J. S. Reis-Filho United Kingdom	14	812 0.8×	1.0k 2.4×	884 2.4×	309 1.0×	219 0.9×	24	2.0k

Countries citing papers authored by Richard Letrero

Since Specialization

Citations

This map shows the geographic impact of Richard Letrero's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Letrero with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Letrero more than expected).

Fields of papers citing papers by Richard Letrero

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Letrero. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Letrero. The network helps show where Richard Letrero may publish in the future.

Co-authorship network of co-authors of Richard Letrero

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Letrero. A scholar is included among the top collaborators of Richard Letrero based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Letrero. Richard Letrero is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Parekh, Vishwas, Joseph F. Sobanko, Christopher J. Miller, et al.. (2018). NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. Journal of Cutaneous Pathology. 46(3). 190–194. 4 indexed citations

Wilson, Melissa, Fengmin Zhao, Richard Letrero, et al.. (2014). Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. Clinical Cancer Research. 20(12). 3328–3337. 30 indexed citations

Nathanson, Katherine L., Anne‐Marie Martin, Bradley Wubbenhorst, et al.. (2013). Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436). Clinical Cancer Research. 19(17). 4868–4878. 132 indexed citations

Chu, Emily Y., Melissa Wilson, Joseph F. Sobanko, et al.. (2013). NRAS and BRAF mutations in atypical melanocytic lesions arising in melanoma patients treated with vemurafenib.. Journal of Clinical Oncology. 31(15_suppl). 9017–9017. 1 indexed citations

Lee, Kam-Pui, Zhaorui Lian, Kurt D’Andrea, et al.. (2013). The FBXO4 Tumor Suppressor Functions as a Barrier to Braf^V600E-Dependent Metastatic Melanoma. Molecular and Cellular Biology. 33(22). 4422–4433. 28 indexed citations

Kanetsky, Peter A., Nandita Mitra, Saran Vardhanabhuti, et al.. (2011). A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Human Molecular Genetics. 20(15). 3109–3117. 94 indexed citations

Nathanson, Katherine L., Alison Martin, Richard Letrero, et al.. (2011). Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436).. Journal of Clinical Oncology. 29(15_suppl). 8501–8501. 29 indexed citations

Kanetsky, Peter A., Nandita Mitra, Saran Vardhanabhuti, et al.. (2009). Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nature Genetics. 41(7). 811–815. 251 indexed citations

Amaravadi, Ravi K., Lynn M. Schuchter, David F. McDermott, et al.. (2009). Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. Clinical Cancer Research. 15(24). 7711–7718. 89 indexed citations

10.

Gordan, John D., Priti Lal, Vijay R. Dondeti, et al.. (2008). HIF-α Effects on c-Myc Distinguish Two Subtypes of Sporadic VHL-Deficient Clear Cell Renal Carcinoma. Cancer Cell. 14(6). 435–446. 392 indexed citations

11.

Smalley, Keiran S.M., Min Xiao, Jessie Villanueva, et al.. (2008). CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene. 28(1). 85–94. 172 indexed citations

12.

Spittle, Cynthia, Maria R. Ward, Katherine L. Nathanson, et al.. (2007). Application of a BRAF Pyrosequencing Assay for Mutation Detection and Copy Number Analysis in Malignant Melanoma. Journal of Molecular Diagnostics. 9(4). 464–471. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact